Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy.

carboplatin de-escalating chemotherapy dysgerminoma germ cell tumours seminoma systemic chemotherapy

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 02 08 2023
accepted: 18 09 2023
medline: 13 11 2023
pubmed: 13 11 2023
entrez: 13 11 2023
Statut: epublish

Résumé

Malignant germ cell tumours are a group of rare cancers whose incidence peaks in late adolescence and early adulthood. Dysgerminomas of the ovary and seminomas of the testis are analogous diseases, but seminomas have a 10-fold higher incidence. The two tumours are morphologically identical and are only differentiated by surrounding organ-specific tissue or testicular germ cell neoplasia

Identifiants

pubmed: 37954076
doi: 10.3389/fonc.2023.1271647
pmc: PMC10634240
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1271647

Informations de copyright

Copyright © 2023 Wood, Bunting, Veli, Arora, Berney, Alifrangis, MacDonald, Miller, Shamash, Stoneham and Lockley.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int J Gynecol Cancer. 2011 Nov;21(8):1414-21
pubmed: 21795985
Gynecol Oncol. 2018 Oct;151(1):61-68
pubmed: 30170975
Cancer Treat Rev. 2008 Aug;34(5):427-41
pubmed: 18378402
Ann Oncol. 2013 Oct;24 Suppl 6:vi125-32
pubmed: 24078656
Urol Oncol. 2016 Mar;34(3):122.e17-22
pubmed: 26612480
Eur J Cancer. 2022 Mar;164:105-113
pubmed: 33041185
Eur Urol. 2014 Dec;66(6):1172-8
pubmed: 25064686
J Clin Oncol. 2021 May 10;39(14):1563-1574
pubmed: 33822655
Cancer. 2015 May 1;121(9):1463-8
pubmed: 25522918
J Clin Oncol. 2004 Sep 1;22(17):3563-9
pubmed: 15337806
Ann Oncol. 2018 Aug 1;29(8):1658-1686
pubmed: 30113631
Endocr Rev. 2013 Jun;34(3):339-76
pubmed: 23575763
J Clin Oncol. 1993 Apr;11(4):598-606
pubmed: 8386751
J Clin Oncol. 2013 Oct 1;31(28):3490-3
pubmed: 24002502
Gynecol Oncol. 2005 Oct;99(1):248-50
pubmed: 16095676
Mol Cancer. 2007 Feb 02;6:12
pubmed: 17274819
Stem Cell Reports. 2016 May 10;6(5):772-783
pubmed: 27132888
J Clin Oncol. 2018 May 20;36(15):1505-1512
pubmed: 29617189
PLoS One. 2015 Apr 10;10(4):e0122146
pubmed: 25859847
Lancet. 2016 Apr 23;387(10029):1762-74
pubmed: 26651223
Gynecol Oncol. 2016 Aug;142(2):261-6
pubmed: 27222024
Gynecol Oncol. 2004 Dec;95(3):496-9
pubmed: 15581952
Otol Neurotol. 2021 Apr 1;42(4):e470-e475
pubmed: 33347049
PLoS One. 2012;7(8):e43952
pubmed: 22937135
Cancer Drug Resist. 2019;2(3):580-594
pubmed: 31538140
Mod Pathol. 2005 Nov;18(11):1411-6
pubmed: 16056250
Ann Oncol. 2017 Jun 1;28(6):1346-1351
pubmed: 28383677
Ann Oncol. 2017 Jun 01;28(6):1333-1338
pubmed: 28327896
Eur J Cancer. 2019 May;113:19-27
pubmed: 30954883
Br J Cancer. 2021 Jan;124(2):368-374
pubmed: 32989229
Ann Oncol. 2015 Jan;26(1):173-178
pubmed: 25361985
Am J Pathol. 1999 Jun;154(6):1643-7
pubmed: 10362788
Eur J Cancer. 2018 Mar;91:30-37
pubmed: 29331749
Eur J Cancer. 2019 Sep;118:49-57
pubmed: 31306943
J Cancer Res Clin Oncol. 2019 Mar;145(3):717-723
pubmed: 30232558
Cancer. 2005 Nov 15;104(10):2255-65
pubmed: 16228988
Lancet. 2005 Jul 23-29;366(9482):293-300
pubmed: 16039331
Adv Urol. 2018 Feb 18;2018:8671832
pubmed: 29670654
Clin Genitourin Cancer. 2016 Dec;14(6):504-510
pubmed: 27055371
Am J Clin Oncol. 2006 Feb;29(1):12-3
pubmed: 16462496
Br J Cancer. 2018 Oct;119(9):1044-1051
pubmed: 30356125
Br J Cancer. 2004 Aug 16;91(4):683-7
pubmed: 15266338
Cancer. 2011 May 15;117(10):2096-103
pubmed: 21523721
Ann Oncol. 2011 Dec;22(12):2654-2660
pubmed: 21415240
Gynecol Oncol. 2017 Feb;144(2):405-413
pubmed: 27931752
Lancet Oncol. 2020 Jul;21(7):e360-e368
pubmed: 32615119
Ann Oncol. 2018 Jan 1;29(1):209-214
pubmed: 29045540
Eur Urol. 2022 Nov;82(5):458-468
pubmed: 35853783
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv1-iv18
pubmed: 29697741
J Clin Oncol. 2000 Nov 15;18(22):3809-18
pubmed: 11078494
Int J Dev Biol. 2013;57(2-4):133-9
pubmed: 23784823
J Clin Oncol. 2006 Oct 20;24(30):4862-6
pubmed: 17050871
JAMA Oncol. 2016 Dec 01;2(12):1624-1627
pubmed: 27711914
Am J Surg Pathol. 2004 Oct;28(10):1341-6
pubmed: 15371950
Gynecol Oncol. 2018 Aug;150(2):253-260
pubmed: 29884437
J Clin Oncol. 1997 May;15(5):1844-52
pubmed: 9164194
Andrology. 2019 Jul;7(4):516-526
pubmed: 31119900
J Cell Mol Med. 2017 Aug;21(8):1463-1467
pubmed: 28244655
Int J Surg Pathol. 2002 Jan;10(1):23-32
pubmed: 11927966
J Clin Oncol. 2004 Jul 1;22(13):2691-700
pubmed: 15226336

Auteurs

Georgina E Wood (GE)

Medical Oncology, University College London Hospital, London, United Kingdom.

Christopher P Bunting (CP)

Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Mesel Veli (M)

Medical Oncology, University College London Hospital, London, United Kingdom.

Rupali Arora (R)

Histopathology, University College London Hospital, London, United Kingdom.

Daniel M Berney (DM)

Histopathology, Barts Health NHS Trust, London, United Kingdom.

Constantine Alifrangis (C)

Medical Oncology, University College London Hospital, London, United Kingdom.

Nicola D MacDonald (ND)

Department of Gynaecology, University College London Hospital, London, United Kingdom.

Rowan E Miller (RE)

Medical Oncology, University College London Hospital, London, United Kingdom.
Medical Oncology, Barts Health NHS Trust, London, United Kingdom.

Jonathan Shamash (J)

Medical Oncology, Barts Health NHS Trust, London, United Kingdom.

Sara Stoneham (S)

Paediatric Oncology, University College London Hospital, London, United Kingdom.

Michelle Lockley (M)

Medical Oncology, University College London Hospital, London, United Kingdom.
Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Classifications MeSH